Citadel Advisors
PDSB icon

Citadel Advisors’s PDS Biotechnology PDSB Stock Holding History

Citadel Advisors’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-386,430
Closed -$390K – 13714
2025
Q3 		$390K Buy
386,430
+137,405
+55% +$162K ﹤0.01% 9729
2025
Q2 		$331K Buy
+249,025
New +$338K ﹤0.01% 9573
2025
Q1 		– Sell
-220,215
Closed -$313K – 15303
2024
Q4 		$359K Buy
220,215
+105,233
+92% +$279K ﹤0.01% 9294
2024
Q3 		$439K Buy
114,982
+66,272
+136% +$221K ﹤0.01% 8529
2024
Q2 		$143K Sell
48,710
-2,655
-5% -$8.49K ﹤0.01% 10415
2024
Q1 		$203K Sell
51,365
-79,017
-61% -$407K ﹤0.01% 10286
2023
Q4 		$648K Buy
130,382
+34,393
+36% +$171K ﹤0.01% 7548
2023
Q3 		$485K Buy
95,989
+45,138
+89% +$247K ﹤0.01% 8119
2023
Q2 		$256K Sell
50,851
-74,056
-59% -$485K ﹤0.01% 9361
2023
Q1 		$768K Buy
124,907
+97,679
+359% +$799K ﹤0.01% 7376
2022
Q4 		$359K Sell
27,228
-91,795
-77% -$648K ﹤0.01% 8931
2022
Q3 		$353K Buy
119,023
+87,106
+273% +$370K ﹤0.01% 9214
2022
Q2 		$116K Sell
31,917
-55,461
-63% -$264K ﹤0.01% 11265
2022
Q1 		$541K Sell
87,378
-32,704
-27% -$203K ﹤0.01% 9202
2021
Q4 		$973K Sell
120,082
-98,965
-45% -$1.06M ﹤0.01% 8035
2021
Q3 		$3.26M Buy
219,047
+130,633
+148% +$1.63M ﹤0.01% 5178
2021
Q2 		$1.11M Buy
+88,414
New +$690K ﹤0.01% 8093
2019
Q1 		– Sell
-3,020
Closed -$19K – 9715
2018
Q4 		$19K Buy
+3,020
New +$40K ﹤0.01% 8769
2018
Q2 		– Sell
-2,862
Closed -$68K – 9155
2018
Q1 		$68K Buy
+2,862
New +$770K ﹤0.01% 7841

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's PDSB Position: Q4 2025 in Review

Citadel Advisors sold out of PDS Biotechnology (PDSB) in Q4 2025, closing a stake of 386,430 shares — an estimated $390K sold.

Citadel Advisors first reported a position in PDSB in Q1 2018 and held it in 19 quarters. The position peaked at $3.26M in Q3 2021. 44 funds tracked by Wall St. Rank hold PDSB as of Q4 2025.

  • Citadel Advisors reported no remaining PDS Biotechnology position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 386,430 PDS Biotechnology shares in Q4 2025, an estimated $390K.
  • Citadel Advisors first reported a position in PDS Biotechnology in Q1 2018 and held it in 19 quarters.
  • Citadel Advisors's PDS Biotechnology position peaked at $3.26M in Q3 2021.
  • 44 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.